A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
NCT07395258
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
BI 3923948
DRUG:
Ezabenlimab
Sponsor
Boehringer Ingelheim